Chronic subdural hematoma as failed resolution at the aged dura-subdural interface: Immune-vascular mechanisms, biomarker interpretation, and therapeutic translation.
Key claim: Chronic subdural hematoma persistence and recurrence in older adults may reflect failed resolution at the aged dura-subdural interface, driven by frailty, immune-vascular aging, and a local immune-vascular-fibrinolytic niche rather than retained clot or technical failure alone.
Abstract
Chronic subdural hematoma (CSDH) is a frequent disorder of older adults, yet its persistence and recurrence are not fully explained by retained clot, bridging-vein injury, or technical failure of evacuation. We propose an aging-informed failed-resolution framework for interpreting CSDH persistence and recurrence at the aged dura-subdural interface. In this model, brain atrophy can maintain a residual subdural space, while frailty, multimorbidity, immune aging, vascular aging, and local fibrinolytic excess may lower the threshold for persistent membrane activity and delayed resolution. These host-level vulnerabilities are proposed to shape the outer-membrane environment, where macrophage and dendritic-cell recruitment, cytokine signaling, pathological angiogenesis, vascular leakage, recurrent microhemorrhage, and fibrin turnover may interact as an immune-vascular-fibrinolytic niche. We distinguish direct CSDH evidence from aging-derived mechanisms that remain inferential. Current CT and MRI phenotypes define hematoma burden, architecture, mass effect, and membrane enhancement, but they do not yet identify biological endotypes or select treatment. Peripheral inflammatory indices, coagulation-fibrinolysis markers, hematoma-fluid mediators, and single-cell profiling should be interpreted according to biological proximity, age-related confounding, and treatment-response validation. Burr-hole evacuation with drainage remains the standard for symptomatic mass effect. Middle meningeal artery embolization (MMAE) currently has the most developed evidence base among membrane-directed adjuncts, whereas corticosteroid trials show that nonselective anti-inflammatory therapy can reduce reoperation yet worsen patient-centered outcomes. A key next step is to link frailty, lesion activity, functional recovery, safety, and treatment response in aging-informed cohorts and trials.
Why this matters
Reframing chronic subdural hematoma as a failed-resolution lesion of the aged dura-subdural interface shifts its mechanistic home from pure neurosurgery into geroscience, treating recurrence as a readout of local immune-vascular-fibrinolytic aging rather than a technical complication. The synthesis offers a concrete tissue context in which inflammaging, immunosenescent clearance failure, and vascular-aging neovascularization converge on a measurable clinical endpoint, and it motivates resolution-pharmacology and senescence-directed biomarkers at a site rarely profiled in aging research. The biology-to-therapy gap remains wide: no new primary data, and the proposed biomarker/therapy agenda has not been tested in CSDH patients.